Clinical Study
Pretreatment Diffusion-Weighted MRI Can Predict the Response to Neoadjuvant Chemotherapy in Patients with Nasopharyngeal Carcinoma
Table 3
Tumor volume and ADCs of the primary tumor and metastatic adenopathies in 92 patients with NPC.
|
Characteristic | Number of patients | -value | Responders () | Nonresponders () |
| Tumor volume (cm3) | | | | NP pretreatment | 37.3 ± 2.7 | 36.2 ± 7.0 | 0.884 | NP posttreatment | 9.1 ± 1.2 | 23.7 ± 4.7 | 0.010 | LN pretreatment | 18.2 ± 1.7 | 20.0 ± 4.6 | 0.708 | LN posttreatment | 2.4 ± 0.5 | 14.3 ± 3.1 | 0.004 | ADC (×10−3 mm2/sec) | | | | NP pretreatment | 0.809 ± 0.009 | 0.953 ± 0.038 | 0.003 | NP posttreatment | 1.276 ± 0.007 | 1.306 ± 0.033 | 0.182 | LN pretreatment | 0.966 ± 0.010 | 1.121 ± 0.045 | 0.007 | LN posttreatment | 1.354 ± 0.009 | 1.355 ± 0.045 | 0.983 | Increase in ADC (%) | | | | NP | 58.5 ± 1.0 | 38.2 ± 3.1 |
<0.001 | LN | 40.4 ± 0.5 | 21.2 ± 1.3 | <0.001 |
|
|
NP = nasopharynx; LN = regional neck lymph nodes.
|